Clinical trials: Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
To learn if treatment with tiragolumab and atezolizumab before and after standard of care surgery and chemoradiation (radiation therapy with or without cisplatin/carboplatin) can help to control OCSCC that is PD-L1 CPS positive.
- Trial name
- NCT05681039
- Testing
- Tiragolumab, Atezolizumab, Standard of Care
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Oral Cancer
Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line
Squamous cell carcinoma (SCC) is the most common oral cavity carcinoma. Conventional therapeutic modalities for oral malignancy include surgery, radiotherapy and chemotherapy alone or in combinations.The major obstacle of using…
- Trial name
- NCT05456022
- Testing
- Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one, Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT), Doxorubicin chemotherapeutic drug as a positive control
- Where
- Egypt
- Volunteers
- 1,000,000 people
- Sponsor
- Cairo University
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
SOTO: Treatment Sensitivity of Organoids to Predict Treatment Outcome
In this study, we aim to assess whether Patient Derived Organoids can be used to predict treatment sensitivity in HNSCC patients.
- Trial name
- NCT05400239
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Laryngeal Squamous Cell Carcinoma
IMP3 and PCNA Expression in Laryngeal Squamous Cell Carcinoma in Sohag Governorate
Laryngeal cancer is responsible for 2-5% of all new cancer cases worldwide. Squamous cell carcinoma of the larynx (LSCC) is the most common malignant tumor of the larynx, accounting for 85-90% of all laryngeal malignancies.
- Trial name
- IMP3PCNA (NCT05293327)
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Sohag University
Esophageal Squamous Cell Carcinoma
Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma
This is a prospective single-arm study of endoscopic resection (ER) following concurrent chemoradiotherapy for stage I esophageal squamous cell carcinoma, to find if the treatment combination is useful by assessing its safety and…
- Trial name
- NCT04275986
- Testing
- Intensity modulated radiotherapy (IMRT), Chemotherapy
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Chinese Academy of Medical Sciences
Head and Neck Cancer
S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00054054
- Testing
- cisplatin, docetaxel, fluorouracil
- Where
- 95 sites in United States, Canada
- Sponsor
- SWOG Cancer Research Network
Oral Squamous Cell Carcinoma (OSCC), Diagnosis
Trop2-targeting NIR-II Molecular Probe for Precision Diagnosis of Oral Cancer
Given the morphological and clinical similarities between certain oral malignant neoplasms and benign conditions such as oral ulcerations or inflammatory lesions, the potential for misdiagnosis is significant.
- Trial name
- NCT07794813
- Testing
- TTP-ICG incubation solution
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Yunnan Cancer Hospital
Esophageal Neoplasm, Head and Neck Neoplasm
The Effects of Upper Airway and Digestive Tract Tumors on the Immune System
The goal of this study is to learn how tumors of the upper airway and digestive passages (tongue, throat, mouth, and voicebox) affect the body's immune defenses and energy storage.
- Conditions
- Esophageal Neoplasm, Head and Neck Neoplasm, Laryngeal Neoplasm, Papilloma
- Trial name
- NCT00001603
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
Esophageal Squamous Cell Carcinoma (ESCC)
Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC
This multicenter, prospective Phase II study investigates a response-adapted organ-preservation strategy in patients with resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- SCOPE (NCT07711470)
- Testing
- Sugemalimab and Chemotherapy, Nab-paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Squamous Cell Carcinoma
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas
The purpose of this study is to explore the safety and feasibility of anti-programmed cell death 1(PD-1) immunotherapy, Camrelizumab, combined with cyclin-dependent kinase 4/6 blockade, Palbociclib, as a new neoadjuvant treatment…
- Trial name
- NCT06654297
- Testing
- Camrelizumab, Palbociclib(100mg), Palbociclib(125mg)
- Where
- China
- Volunteers
- 6 people
- Sponsor
- West China Hospital
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Trial name
- NCT05136196
- Testing
- Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate
- Where
- 232 sites in United States
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute (NCI)
Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor
Collecting Tumor Samples From Patients With Gynecological Tumors
This laboratory study is collecting tumor tissue and blood samples from patients with gynecologic tumors. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help in…
- Conditions
- Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
- Trial name
- NCT00897442
- Testing
- Laboratory Biomarker Analysis
- Where
- 187 sites in United States
- Volunteers
- 275 people
- Sponsor
- Gynecologic Oncology Group
Hearing Loss, Head and Neck Cancer
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
Background: Cisplatin is used to treat head and neck cancer. People who take this drug are at risk for hearing loss. Atorvastatin is a drug used to treat high cholesterol.
- Trial name
- NCT04915183
- Testing
- Atorvastatin
- Where
- 5 sites in United States
- Volunteers
- 224 people
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
Esophageal Cancer
Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer
The goal of this clinical trial is to evaluate the safety, tolerance and efficacy of Utidelone combined with Anlotinib in patients with Advanced or Recurrent Esophageal Carcinoma who failed Standard first line therapy.
- Trial name
- NCT05866510
- Testing
- Utidelone and anlotinib
- Where
- 3 sites in China
- Volunteers
- 47 people
- Sponsor
- Peking University
Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Prospective, open, non-interventional, multi-center clinical registry study with the aim to establish a comprehensive research platform reflecting the real-world treatment landscape for recurrent/metastatic head and neck tumor…
- Conditions
- Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Hypopharynx, Squamous Cell Carcinoma of the Larynx
- Trial name
- HEAT (NCT06380686)
- Testing
- data collection
- Where
- 2 sites in Germany
- Volunteers
- 120 people
- Sponsor
- AIO-Studien-gGmbH
Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer
Improved Oral Health in Head and Neck Cancer Survivors
The goal of this clinical trial is to learn if an oral care programme, designed as a multicentre two-armed randomised controlled trial (RCT), can prevent or mitigate late oral sequalae following completion of head and neck cancer…
- Trial name
- OHHNC (NCT07173270)
- Testing
- Oral health support
- Where
- Sweden
- Volunteers
- 300 people
- Sponsor
- Uppsala University
Head and Neck Cancer
Towards A Better Paradigm for Head and Neck Cancer Treatment Applying Artificial Intelligence. HNC-TACTIC.
This will be an international, multicenter, retrospective, observational, and data-driven study using secondary data captured in EHRs.
- Trial name
- HNC-TACTIC (NCT05117775)
- Testing
- No intervention - Just description and predictive models
- Where
- Spain
- Volunteers
- 10,000 people
- Sponsor
- Savana Research
Head and Neck Cancer
Chemotherapy Plus Radiation Therapy in Treating Patients With Squamous Cell Cancer of the Head and Neck
The purpose of this research study is to develop a new chemo radiotherapy regimen for the treatment of cancer of the head and neck for patients who have received induction chemotherapy; and to determine the highest dose of…
- Trial name
- NCT00003200
- Testing
- Taxotere, Radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Dana-Farber Cancer Institute
Esophageal Neoplasms
Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
There is no standard treatment strategy for recurrent or metastatic esophageal squamous cell carcinoma patients now, especially after the second-line treatment.
- Trial name
- NCT03274011
- Testing
- Apatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.